Diseasemodifying drugs - Biotech, Pharma and Life Science Channel

00:03 EDT 1st October 2014 | BioPortfolio

PubMed Articles [4655 Associated PubMed Articles listed on BioPortfolio]

In brief: Khedzela - a new brand of desvenlafaxine.

New oral anticogulants for acute venous thromboembolism.

Simeprevir (Olysio) for chronic hepatitis c.

How to Treat Erectile Dysfunction in Men with Diabetes: from Pathophysiology to Treatment.

Erectile dysfunction (ED) is highly prevalent affecting at least 50 % of men with diabetes mellitus (DM). DM may cause ED through a number of pathophysiological pathways. These include neuropathy, en...

Qualitative screening of 116 veterinary drugs in feed by liquid chromatography-high resolution mass spectrometry: Potential application to quantitative analysis.

Veterinarian and human pharmaceuticals may be intentionally added to animal feed to enhance animal production. Monitoring these substances is necessary for protecting the consumers. In this work, a sc...

Urologic Pathology: CBS25-1 THE ANTI-TUMOR MECHANISM OF TYROSINE KINASE INHIBITORS IN CLEAR CELL RENAL CELL CARCINOMAS: INSIGHTS FROM A PATHOLOGIC ASSESSMENT.

Angiogenesis occurs during tumor development and plays a critical role in the progression of clear cell renal cell carcinoma (CCRCC). Tyrosine kinase inhibitors (TKIs) are multi-target inhibitors of T...

Pulmonary Pathology: SY22-1 IMMUNOHISTOCHEMISTRY FOR LUNG CANCER PREDICTIVE BIOMARKERS.

In the past decade, we have observed tremendous advance in the treatment for NSCLC. The discovery of sensitizing EGFR mutations as the basis of clinical response to tyrosine kinase inhibitors (TKIs) h...

Pulmonary Pathology: LC22-1 PULMONARY HYPERTENSION.

Pulmonary hypertension is a disease that is characterized by an increased pulmonary artery pressure and often results in right ventricular failure. Patients of any age might present with exertional dy...

Pediatric and Perinatal Pathology: SY21-5 NEUROBLASTOMA: MOLECULAR TARGETS AND NOVEL THERAPIES.

The MYCN oncogene is the single most powerful biologic prognostic factor yet identified in childhood neuroblastoma. Children whose tumours display MYCN amplification have a particular poor prognosis, ...

Neuropathology: SY21-2 MUCOR FUNGAL ENCEPHALITIS: CASE PRESENTATION.

Mucormycosis is a rare and often fatal infection caused by fungi of the Mucorales order, commonly affecting immunocompromised patients and adults with diabetic ketoacidosis. Infants are infected throu...

News Articles [5358 Associated News Articles listed on BioPortfolio]

U.S. considering experimental drugs for Texas Ebola patient -CDC

Sept 30 (Reuters) - The United States is discussing the possible use of experimental drugs or blood plasma from a recovered Ebola patient as a potential treatment for a patient in Texas diagnosed with...

FDA Twitter Policy Offers Loophole For Promoting Black-Box Drugs

What you might have missed in FDA’s social media guidance: “Reminder-like” promotion utilizes “one-click” rule, allowing companies to promote drugs with excessive risk in space limited Inter...

Drug Rehab in Florida, Destination Hope, Applauds NFL for New Drug Abuse Policy

A growing number of employers are reviewing and revising substance use policies. Fort Lauderdale, Fla (PRWEB) September 30, 2014 For the first time since 2010, the National Football League (NFL) has ...

Novartis ordered to face U.S. lawsuit over doctor kickbacks

NEW YORK, Sept 30 (Reuters) - A federal judge said Novartis AG must face a U.S. government lawsuit accusing the Swiss drugmaker of paying multimillion-dollar kickbacks, including a $9,750 dinner for t...

Indian government takes action over dubious fixed-dose combinations

In a bid to weed out potentially unsafe combinations, the Central Drugs Standards and Control Organization (CDSCO), headed by the Drug Controller General of India (DCGI), is to assess the safety and e...

EMA Pilot Eventually Could See Permanent Patient Presence At The CHMP

The EMA has launched a pilot project allowing patients to contribute to discussions in its senior scientific body, the CHMP, which initially could benefit manufacturers of drugs for unmet medical need...

Where is the evidence for the existence of the Cancer Drugs Fund?

Professor Peter Clark congratulates the Cancer Drugs Fund (CDF) for reimbursing drugs only at the lowest price proposed for use in the NHS, but he is later quoted conceding that “some...

Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies

LONDON, Sept. 30, 2014 /PRNewswire/ -- STUDY OBJECTIVESThe objective of BCC in conducting this study is to provide an overview of the current and future characteristics of the global market for protei...

Growing Patient Pool and Favorable Regulations Spur the Global Market for Pediatric Drugs and Vaccines, According to New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Pediatric Drugs and Vaccines markets. Global market for Pediatric Drugs and Vaccines is forecast to reach US$100 billion by 2020, spurred ...

New cancer therapy comes of age, cost a 'toxic' side effect

MADRID (Reuters) - A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects -- but their high cost is a growing concern.

Events [0 Results]

None

Companies [226 Associated Companies listed on BioPortfolio]

PharmaEngine, Inc.

PharmaEngine, Inc. is a biopharmaceutical company established in Taipei, Taiwan in 2003. The company focuses on the development of new drugs to treat cancer and Asian prevalent di...

Retina Associates of Florida

Retina Associates is a state-of-the art diagnostic and treatment center as well as a leading clinical research center for macular degeneration and other retinal diseases. Its phys...

BioFilm, Ltd.

Founded in 2003 as a subsidiary of Devro plc., BioFilm is the largest Thin Dissolving Film (TDF) producer in Europe, with their GMP certified manufacturing and packaging facility ...

Catalent, Inc.

Catalent, Inc. is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years ser...

Biosceptre

Biosceptre has identified a pan-cancer target, present in many cancer types, and importantly not found in healthy tissue. Early research and initial evidence suggest that drugs di...

Therapeutic Proteins International

Therapeutic Proteins International, LLC (TPI) is a fully integrated manufacturer of biosimilar recombinant protein products. TPI’s vision is to produce high quality, life-alt...

Sephos Biotherapeutics

Sephos Biotherapeutics is a privately owned company focused on designing drugs for the treatment of cancer stem cells where the structure and biological activity of the drugs have...

BIOCAD

Based in St. Petersburg, Russia, joint-stock company BIOCAD is a leading Russian private biopharmaceutical company, specializing in the research, development and manufacture of ge...

DesignMedix, Inc.

DesignMedix, Inc. was founded in 2008 to develop drugs to overcome drug resistance. The company’s initial focus is on oral drugs to treat malaria, which kills over 600,000 pe...

Zarbee’s Naturals

Founded in 2008 by pediatrician Dr. Zak Zarbock, Zarbee’s Naturals manufactures the nation’s #1 natural cough syrup and a complete line of “family-safe” health...

Clinical Trials [142 Associated Clinical Trials listed on BioPortfolio]

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the...

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

The purpose of this study is to find out whether taking protease inhibitors (anti-HIV drugs) together with lipid-lowering drugs (drugs which lower the amount of fat in the blood) has an ef...

A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

The purpose of this study is to see if it is safe and effective to give efavirenz plus stavudine plus lamivudine to patients who have never taken anti-HIV drugs.

A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs

To evaluate the mechanism whereby thymopentin appears to retard the progressive immune suppression attributable to HIV infection.

A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs

To make stavudine (d4T) available to patients with advanced HIV disease for whom no alternative antiretroviral is satisfactory. To study the safety and efficacy of two dose levels in a twi...

The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs

To evaluate the tolerance, safety, and effectiveness of Viramune in preventing clinical AIDS progression events or death when used in combination with Lamivudine and background nucleoside ...

A Study of MKC-442 in Combination With Other Anti-HIV Drugs

The purpose of this study is to see if it is safe and effective to give MKC-442 plus stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.

A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs

The purpose of this study is to compare the safety of didanosine plus stavudine plus nelfinavir (NLF) with that of zidovudine plus lamivudine plus NLF. This study also examines how long th...

A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs

The purpose of this study is to see if it is safe and effective to give one of three different triple-drug combinations to HIV-infected patients who have never been treated with anti-HIV d...

A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

To evaluate the tolerance, and comparative virologic and immunologic effects of the two combination regimens.

Medical and Biotech [MESH] Definitions

Drugs used by veterinarians in the treatment of animal diseases. The veterinarian's pharmacological armamentarium is the counterpart of drugs treating human diseases, with dosage and administration adjusted to the size, weight, disease, and idiosyncrasies of the species. In the United States most drugs are subject to federal regulations with special reference to the safety of drugs and residues in edible animal products.

Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.

The use of multiple drugs administered to the same patient, most commonly seen in elderly patients. It includes also the administration of excessive medication. Since in the United States most drugs are dispensed as single-agent formulations, polypharmacy, though using many drugs administered to the same patient, must be differentiated from DRUG COMBINATIONS, single preparations containing two or more drugs as a fixed dose, and from DRUG THERAPY, COMBINATION, two or more drugs administered separately for a combined effect. (From Segen, Dictionary of Modern Medicine, 1992)

Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here.

Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. While no potent nootropic drugs have yet been accepted for general use, several are being actively investigated.

Search BioPortfolio:
Loading
Advertisement
Advertisement
review and buy Diseasemodifying drugs market research data and corporate reports here

Channels Quicklinks